Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463695 | 0.90 | S1PR1 (0.46) | ITGB3ITGA2BPPARGS1PR1ALOX5 | |
| SCHEMBL17733495 | 0.86 | ITGB3 (0.43) | ITGB3ITGA2BITGAVPPARGS1PR1 | |
| SCHEMBL79822 | 0.85 | S1PR1 (0.35) | S1PR1 | |
| SCHEMBL86580 | 0.83 | ITGB3 (0.40) | ITGB3ITGA2BITGAVPPARGS1PR1 | |
| SCHEMBL78875 | 0.83 | ITGB3 (0.40) | ITGB3ITGA2BITGAVPPARGS1PR1 | |
| SCHEMBL80550 | 0.81 | PPARG (0.36) | ITGB3ITGA2BITGAVPPARGS1PR1 | |
| SCHEMBL81201 | 0.80 | S1PR1 (0.33) | ITGB3ITGA2BPPARGS1PR1 | |
| SCHEMBL80081 | 0.76 | AAK1 (0.35) | ITGB3ITGA2BPPARGS1PR1 | |
| SCHEMBL80501 | 0.75 | S1PR1 (0.47) | PPARGS1PR1HPGDALOX5NAAA | |
| SCHEMBL2466970 | 0.75 | S1PR1 (0.59) | ITGB3ITGA2BPPARGS1PR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | ITGB3 4646/4885ITGA2B 4585/4885ITGAV 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.